Study Results from McGill University Health Center Provide New Insights into Ulcerative Colitis (Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the Unifi Long-term Maintenance Study).

A study conducted by McGill University Health Center in Montreal, Canada, has provided new insights into the efficacy and safety of ustekinumab for the treatment of ulcerative colitis (UC). The study followed patients with UC who received ustekinumab for four years and found that 55.2% of patients were in symptomatic remission at week 200. The study also showed that a greater proportion of biologic-naive patients achieved symptomatic remission compared to those with a history of biologic failure. No new safety signals were observed during the study. The findings confirm the long-term efficacy of ustekinumab for the treatment of UC. [Extracted from the article]

Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)